Morgan Stanley Maintains Equal-Weight on NeuroPace, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Drew Ranieri maintains an Equal-Weight rating on NeuroPace (NASDAQ:NPCE) but lowers the price target from $9.5 to $8.
July 15, 2024 | 4:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating on NeuroPace but has lowered the price target from $9.5 to $8, indicating a more cautious outlook.
The lowered price target from $9.5 to $8 by Morgan Stanley suggests a more cautious outlook on NeuroPace's stock performance. This could lead to a short-term negative impact on the stock price as investors may adjust their expectations accordingly.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100